REGULATORY INTELLIGENCE·Recall
FDA Class II Recall: Subpotent Semaglutide Injection from Boothwyn Pharmacy LLC Raises Quality Concerns
Boothwyn Pharmacy LLC has initiated a Class II nationwide recall for 186 vials of subpotent Semaglutide, 2.5 mg/mL injection. This event underscores critical quality control vulnerabilities in pharmaceutical compounding. Procurement and regulatory teams must enhance vigilance over supplier potency testing and manufacturing compliance to mitigate significant supply chain and patient safety risks.
90-Day Activity
Boothwyn Pharmacy LLCSemaglutide
MKMeera Krishnan· Senior Regulatory Intelligence Analyst2025-09-10